TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00408330
Drug: Inactive 15% gel base
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, topically applied daily for six weeks
Study: NCT03743883
Drug: Acetylsalicylic Acid(BAYE4465, Aspirin )
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration according to clinical practice
Study: NCT00844207
Drug: Fixed combination of Azithromycin and Chloroquine
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
Study: NCT00844207
Drug: Azithromycin and Chloroquine
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
Study: NCT01925352
Drug: Ad-HGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
Study: NCT02885948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, ineffective control arm
Study: NCT05986292
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT05986292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV
Study: NCT01017458
Drug: MK0773
DrugBank: MK-0773 (DB16244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 25mg oral tablets MK0773 bid, for 12 weeks
Study: NCT01017458
Drug: Comparator: testosterone enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
Study: NCT01017458
Drug: Comparator: placebo oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablet bid, for 12 weeks
Study: NCT01017458
Drug: Comparator: placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intramuscular injection q14d, for 12 weeks
Study: NCT02301910
Drug: Recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Study: NCT03764488
Drug: 99mTc-MAG3-BIIB067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT01171664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, one BID
Study: NCT04119739
Drug: Ibuprofen Arginine
Normalized name: ibuprofen arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01171664
Drug: STAHIST
Normalized name: Stahist
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAHIST in tablet form dosed one BID
Study: NCT02686021
Drug: Metamizole and Ibuprofen
Normalized name: hydrocodone and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study: NCT02686021
Drug: Ibuprofen and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study: NCT02845882
Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Study: NCT02845882
Drug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
Study: NCT02845882
Drug: Methotrexate, 6-mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
Study: NCT03758989
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study: NCT03758989
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study: NCT02811055
Drug: Administration of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo once per day during 14 days
Study: NCT02869295
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
Study: NCT00207714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
Study: NCT04123795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use
Study: NCT00812344
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, dosing through the Loc-I-Gut catheter, single dose
Study: NCT01057901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the matched placebo which will be administered two tablets daily at bedtime.
Study: NCT01036061
Drug: GSK618334 PET subjects
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET subjects
Study: NCT01036061
Drug: GSK618334 Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Dose
Study: NCT00803946
Drug: Ibuprofen Tablets, 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03825471
Drug: Opioid Anesthetics
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: consumption of opioids during general anesthesia
Study: NCT03503708
Drug: Livitol-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
Study: NCT00005036
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005036
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00314249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral administration, twice daily for 12 weeks
Study: NCT02129660
Drug: Dose 1 of glycopyrrolate, 2.0% QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 of glycopyrrolate Topical Wipes
Study: NCT02129660
Drug: Dose 2 of glycopyrrolate, 3.0% QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 of glycopyrrolate Topical Wipes
Study: NCT01092299
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER Fast, 90mg, p.o. capsule
Study: NCT01092299
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER Moderate, 90mg, p.o. capsule
Study: NCT01092299
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER Slow, 90mg, p.o. capsule
Study: NCT01092299
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR
Study: NCT01092299
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR, 90 mg p.o. capsule
Study: NCT02503345
Drug: ALLN-177 mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
Study: NCT01092299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR
Study: NCT01092299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER/MR
Study: NCT02503345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
Study: NCT02345928
Drug: Part 1: CNTO 7160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
Study: NCT03245229
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral administration
Study: NCT00630682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 weeks of placebo 60mg capsules QD.
Study: NCT00745615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
Study: NCT01918111
Drug: adenosine infusion treatment
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue hypertensive medication
Study: NCT04582097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same odor, color and size as the drug but without the active ingredient
Study: NCT03970720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg matching placebo capsules four times a day
Study: NCT03011463
Drug: oral administration of 500 mg clarithromycin
Normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of 500 mg clarithromycin with 240 ml tap water
Study: NCT04485286
Drug: [68Ga]CBP8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
Study: NCT00543790
Drug: PRA-027
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
Study: NCT01131728
Drug: Naproxen Sodium & Pseudoephedrine HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Study: NCT01967888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic solution administered at 0.25 mL/kg/hour
Study: NCT00183469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
Study: NCT00965913
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
Study: NCT02366065
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
Study: NCT04540120
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard opaque capsules containing 0 mg of API.
Study: NCT02577042
Drug: PI-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
Study: NCT01347879
Drug: Visonac PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream application prior to illumination with red light
Study: NCT01347879
Drug: Vehicle cream with PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/vehicle cream application prior to illumination with red light
Study: NCT01965535
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study: NCT00970931
Drug: Chlorthalidone plus amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
Study: NCT00970931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo once a day, for 18 months
Study: NCT01493531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Placebo QD
Study: NCT01303874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN-matching placebo SC injections once weekly and MTX orally once weekly.
Study: NCT01807962
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo = 5ml of sterile saline solution
Study: NCT03854227
Drug: PF-06939999 dose escalation
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06939999 orally at escalating doses on a continuous basis
Study: NCT03640468
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive normal saline 10 mL
Study: NCT01554969
Drug: capecitabine + ganetespib
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily.
Study: NCT04169386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose administered subcutaneously
Study: NCT01027884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
Study: NCT00782327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo capsule
Study: NCT03670043
Drug: Psyllium powder
Normalized name: psyllium Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate whether Psyllium will alleviate diarrhea
Study: NCT00844727
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00844727
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT02907554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group receives a placebo
Study: NCT04438629
Drug: COVID-19 treatment
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
Study: NCT03936959
Drug: LY3434172
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00701935
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, twice a day
Study: NCT01486485
Drug: heparinized saline priming group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01486485
Drug: nafamostat infusion after heparinized saline priming
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01539317
Drug: Topical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline applied to the vestibule mucosa will not reverse the local tenderness
Study: NCT00553865
Drug: OJP-2028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Study: NCT01328171
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study: NCT00021320
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01236105
Drug: LY2624803
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (po), once.
Study: NCT01668927
Drug: Proton Pump Inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668927
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02250027
Drug: HL301 300mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules at once, 3 times a day, for 7 days
Study: NCT02250027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules at once, 3 times a day, for 7 days
Study: NCT04623385
Drug: The standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: infected patients will receive the standard therapy for COVID-19 for 14 days
Study: NCT02217345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
Study: NCT02857725
Drug: BAY 987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT01068925
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days
Study: NCT00800683
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching BI 1356 taken once daily
Study: NCT02857725
Drug: SPF 15 Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT02179359
Drug: Reduced Toxicity Ablative Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0
Study: NCT02179359
Drug: Reduced Intensity Preparative Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0
Study: NCT02179359
Drug: Myeloablative Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0
Study: NCT03965078
Drug: topical (eye drop) anti-inflammatories
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
Study: NCT00457873
Drug: 0.9% saline in 5% dextrose (intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01318252
Drug: AL-54478 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02615730
Drug: GSK2636771
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
Study: NCT04411524
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Study: NCT00475852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Study: NCT02065791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally (by mouth) once daily
Study: NCT02449720
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal instillation and infusion
Study: NCT03759288
Drug: Humira®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
Study: NCT03759288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
Study: NCT03010761
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Cap
Study: NCT03280095
Drug: co-codamol 30mg/500mg tablet
Normalized name: Co-Gesic 5 MG / 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02713243
Drug: LJN452
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing LJN452
Study: NCT00447018
Drug: 7.45% hypertonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01335464
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching BIBF1120, BID
Study: NCT01335464
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF1120 BID (twice daily)
Study: NCT03582293
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule two times a day for a total of 28 days
Study: NCT02677805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
Study: NCT03409614
Drug: REGN2810/chemo/ipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
Study: NCT03409614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Part 2
Study: NCT02535000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02175407
Drug: ASP1707
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03779113
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HMPL-523